NVOS RSI Chart
Last 7 days
-17.2%
Last 30 days
-5.9%
Last 90 days
-34.2%
Trailing 12 Months
226.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 13.7M | 0 | 0 | 0 |
2023 | 12.2M | 12.4M | 12.6M | 13.0M |
2022 | 8.9M | 20.3M | 11.7M | 11.9M |
2021 | 7.1M | 8.5M | 7.1M | 8.1M |
2020 | 9.9M | 8.4M | 7.9M | 7.5M |
2019 | 9.0M | 9.2M | 9.4M | 9.7M |
2018 | 8.7M | 8.9M | 8.9M | 9.0M |
2017 | 7.6M | 7.8M | 8.0M | 8.4M |
2016 | 0 | 0 | 7.2M | 7.4M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 20, 2022 | oliva robert letterio | bought | 11,156 | 2.2312 | 5,000 | - |
Apr 19, 2022 | oliva robert letterio | bought | 11,125 | 2.225 | 5,000 | - |
Apr 21, 2021 | oliva robert letterio | bought | 27,560 | 2.12 | 13,000 | - |
Feb 23, 2021 | oliva robert letterio | bought | 890 | 4.45 | 200 | - |
Feb 22, 2021 | oliva robert letterio | bought | 40,320 | 4.31 | 9,355 | - |
Which funds bought or sold NVOS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -13,245 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 22.89 | -2,002 | 5,385 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -74.05 | -257 | 46.00 | -% |
May 15, 2024 | MORGAN STANLEY | unchanged | - | -2.00 | 2.00 | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | -11,109 | 16,214 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | sold off | -100 | -95,777 | - | -% |
May 15, 2024 | Royal Bank of Canada | unchanged | - | -2,000 | 4,000 | -% |
May 14, 2024 | NORTHERN TRUST CORP | unchanged | - | -9,315 | 13,595 | -% |
May 13, 2024 | UBS Group AG | sold off | -100 | -9,945 | - | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | unchanged | - | -42,711 | 62,343 | -% |
Unveiling Novo Integrated Sciences, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Novo Integrated Sciences, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
UNH | 482.9B | 379.5B | 31.44 | 1.27 | ||||
CI | 96.2B | 206.0B | 24.97 | 0.47 | ||||
HCA | 84.6B | 66.7B | 15.46 | 1.27 | ||||
CVS | 72.4B | 360.9B | 9.89 | 0.2 | ||||
CNC | 41.7B | 155.5B | 15.24 | 0.27 | ||||
DVA | 12.3B | 12.3B | 15.03 | 0.99 | ||||
UHS | 11.9B | 14.7B | 14.63 | 0.81 | ||||
MID-CAP | ||||||||
CHE | 8.5B | 2.3B | 30.15 | 3.73 | ||||
ACHC | 6.2B | 3.0B | -545.12 | 2.06 | ||||
AMEH | 2.3B | 1.5B | 36.62 | 1.57 | ||||
AMN | 2.2B | 3.5B | 15.49 | 0.64 | ||||
SMALL-CAP | ||||||||
ADUS | 1.8B | 1.1B | 27.59 | 1.67 | ||||
BKD | 1.3B | 3.0B | -7.66 | 0.44 | ||||
BEAT | 54.5M | - | -3.61 | - | ||||
AMS | 22.0M | 21.6M | 39.79 | 1.02 |
Novo Integrated Sciences, Inc. News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -18.5% | 3,170,592 | 3,891,218 | 3,303,297 | 3,292,933 | 2,556,509 | 3,419,280 | 8,635,582 | 13,851,883 | 2,869,223 | 3,161,927 | 446,390 | 2,380,974 | 2,075,894 | 2,155,506 | 1,844,867 | 1,038,226 | 2,428,864 | 2,548,610 | 2,420,218 | 2,489,575 | 2,200,410 |
Cost Of Revenue | -5.2% | 1,846,506 | 1,947,200 | 2,375,112 | 1,978,839 | 1,585,606 | 1,679,747 | -8,052,632 | 11,443,001 | 1,652,869 | 1,895,461 | 1,713,237 | 1,100,516 | 1,324,448 | 1,344,056 | 1,023,418 | 559,976 | 1,585,860 | 1,632,941 | 1,596,693 | 1,556,865 | 1,320,740 |
Gross Profit | -31.9% | 1,324,086 | 1,944,018 | 928,185 | 1,314,094 | 970,903 | 1,739,533 | -92,464 | 2,408,882 | 1,216,354 | 1,266,466 | 979,644 | 1,280,458 | 751,446 | 811,450 | 821,449 | 478,250 | 843,004 | 915,669 | 823,525 | 932,710 | 879,670 |
Operating Expenses | -45.6% | 2,863,854 | 5,261,655 | 4,022,159 | 2,744,512 | 2,757,713 | 3,981,493 | 20,247,132 | 3,611,628 | 3,337,030 | 2,630,125 | 2,867,523 | 1,682,430 | 2,077,390 | 1,569,174 | 4,777,903 | 556,801 | 993,772 | 992,494 | 1,251,955 | 995,838 | 958,357 |
S&GA Expenses | -73.0% | 2,590 | 9,586 | 5,233 | 1,877 | 707 | 7,332 | -15,638 | 9,802 | 26,370 | 168 | 3,299 | 2,381 | 602 | 1,243 | 426 | 2,389 | 884 | 1,222 | 6,846 | 3,846 | 4,016 |
EBITDA Margin | 20.7% | -0.69 | -0.87 | -0.84 | -2.32 | -2.52 | -2.57 | -2.43 | -0.39 | -0.58 | -0.40 | -0.37 | -0.50 | -0.60 | - | - | - | - | - | - | - | - |
Interest Expenses | 206.0% | 138,684 | 45,321 | 88,216 | 67,888 | 123,866 | 186,911 | 207,907 | - | 1,230,390 | 64,522 | 96,250 | 21,701 | 22,948 | 19,642 | -31,072 | 48,245 | 37,717 | 40,329 | 117,712 | 35,154 | 34,509 |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | 41.1% | -2,745,560 | -4,660,723 | -3,202,251 | -1,485,295 | -4,645,162 | -3,936,736 | -22,638,856 | -3,744,025 | -4,868,204 | -1,816,395 | -1,941,970 | -415,271 | -1,340,591 | -773,103 | -4,228,398 | -101,023 | -505,829 | -88,959 | 76,758 | -100,773 | -122,980 |
EBT Margin | 17.5% | -0.89 | -1.07 | -1.06 | -2.65 | -2.88 | -2.95 | -2.82 | -0.61 | -1.02 | -0.68 | -0.63 | -0.80 | -0.91 | - | - | - | - | - | - | - | - |
Net Income | 41.1% | -2,746,128 | -4,660,723 | -3,159,792 | -1,497,330 | -4,621,355 | -3,936,736 | -22,390,984 | -3,810,054 | -4,868,204 | -1,816,395 | 549,666 | -411,187 | -1,340,591 | -773,103 | -4,014,728 | -98,295 | -505,829 | -88,959 | 82,515 | -99,258 | -122,980 |
Net Income Margin | 17.3% | -0.88 | -1.07 | -1.05 | -2.63 | -2.86 | -2.93 | -2.80 | -0.49 | -0.74 | -0.37 | -0.28 | -0.77 | -0.88 | - | - | - | - | - | - | - | - |
Free Cashflow | 20.4% | -1,713,595 | -2,152,358 | -259,126 | -856,917 | -877,779 | -277,432 | 676,567 | -3,548,612 | -2,322,768 | -879,500 | -800,102 | -50,259 | -282,287 | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -6.2% | 34,949 | 37,244 | 35,563 | 35,745 | 36,489 | 37,749 | 40,873 | 71,793 | 70,320 | 63,934 | 61,958 | 42,228 | 34,857 | 34,836 | 35,391 | 36,572 | 36,640 | 32,104 | 32,273 | 31,682 | 29,081 |
Current Assets | -26.3% | 5,019 | 6,809 | 4,388 | 3,998 | 4,051 | 4,457 | 5,732 | 20,079 | 19,015 | 12,243 | 11,134 | 10,832 | 3,605 | 4,155 | 4,295 | 3,929 | 4,114 | 4,168 | 4,099 | 4,588 | 4,503 |
Cash Equivalents | -60.3% | 652 | 1,640 | 416 | 464 | 610 | 879 | 2,179 | 12,677 | 15,944 | 8,801 | 8,293 | 8,367 | 1,698 | 1,970 | 2,068 | 1,394 | 1,209 | 1,932 | 2,084 | 2,478 | 2,374 |
Inventory | -25.5% | 947 | 1,271 | 1,107 | 939 | 925 | 1,010 | 879 | 645 | 334 | 364 | 339 | - | - | - | - | - | - | - | - | - | - |
Net PPE | -1.1% | 5,246 | 5,307 | 5,390 | 5,411 | 5,449 | 5,564 | 5,801 | 5,932 | 6,158 | 6,097 | 6,070 | 550 | 318 | 333 | 354 | 347 | 368 | 392 | 410 | 418 | 427 |
Goodwill | 0.1% | 7,561 | 7,555 | 7,582 | 7,543 | 7,539 | 7,596 | 7,826 | 11,367 | 9,059 | 8,956 | 9,489 | 688 | 652 | 640 | 637 | 603 | 619 | 625 | 623 | 584 | 600 |
Liabilities | -6.5% | 13,059 | 13,960 | 11,064 | 9,454 | 9,526 | 17,064 | 18,825 | 27,365 | 25,805 | 20,266 | 18,154 | 5,617 | 5,722 | 5,687 | 5,819 | 5,974 | 6,340 | 6,531 | 6,729 | 6,368 | 4,252 |
Current Liabilities | -8.8% | 9,959 | 10,916 | 7,905 | 6,209 | 6,178 | 12,565 | 14,075 | 12,730 | 11,554 | 15,653 | 8,464 | 3,524 | 3,658 | 2,595 | 2,600 | 2,530 | 2,662 | 2,948 | 3,028 | 4,579 | 3,037 |
Shareholder's Equity | -4.7% | 22,189 | 23,284 | 24,816 | 26,567 | 26,963 | 20,685 | 22,048 | 44,428 | 44,515 | 43,668 | 43,804 | 36,610 | 29,135 | 29,149 | 29,572 | 30,599 | 30,300 | 25,574 | 25,544 | 25,313 | 24,829 |
Retained Earnings | -3.8% | -74,459 | -71,713 | -67,033 | -63,872 | -62,375 | -57,753 | -53,818 | -31,391 | -27,581 | -22,775 | -20,969 | -19,029 | -18,618 | -17,278 | -16,507 | -12,282 | -12,184 | -11,680 | -11,591 | -11,670 | -11,570 |
Additional Paid-In Capital | 0.6% | 96,083 | 95,481 | 90,973 | 89,250 | 88,321 | 69,135 | 66,085 | 64,621 | 60,692 | 55,092 | 54,579 | 54,298 | 46,155 | 45,033 | 44,905 | 41,614 | 41,166 | 35,926 | 35,813 | 35,695 | 35,048 |
Accumulated Depreciation | - | 1,378 | - | 1,253 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shares Outstanding | 2.6% | 17,748 | 17,291 | 15,759 | 14,486 | 7,933 | 3,386 | 3,118 | 2,850 | 2,874 | 2,692 | 2,661 | 2,419 | 2,363 | - | - | - | - | - | - | - | - |
Minority Interest | 0.3% | -298 | -299 | -316 | -275 | -287 | -262 | -257 | 55.00 | -36.29 | 26.00 | -60.26 | -60.63 | -53.40 | -51.72 | -49.86 | -43.14 | -41.51 | -40.59 | -39.63 | -37.65 | -37.10 |
Float | - | - | - | - | - | 16,083 | - | - | - | 14,672 | - | - | - | 28,576 | - | - | - | 17,071 | - | - | - | 67,113 |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 20.4% | -1,713 | -2,152 | -228 | -857 | -878 | -278 | 676 | -3,550 | -2,250 | -759 | -745 | 150 | -281 | -148 | -15.56 | 153 | -281 | -297 | -291 | -71.43 | -296 |
Cashflow From Investing | - | - | - | -30.35 | - | - | - | 805* | 326 | -72.14 | -91.11 | 3,681 | -680 | - | - | 925 | -2.70 | -379 | 114 | -136 | -404 | -227 |
Cashflow From Financing | -99.9% | 3.00 | 3,296 | 468 | 901 | 429 | -1,034 | -11,229 | -37.24 | 9,440 | 1,400 | -2,845 | 7,141 | -22.33 | 44.00 | -315 | 71.00 | -57.11 | 30.00 | -3.13 | 639 | 1,940 |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Feb. 29, 2024 | Feb. 28, 2023 | Feb. 29, 2024 | Feb. 28, 2023 | |
Income Statement [Abstract] | ||||
Revenues | $ 3,170,592 | $ 2,556,509 | $ 7,061,810 | $ 5,975,789 |
Cost of revenues | 1,846,506 | 1,585,606 | 3,793,706 | 3,265,353 |
Gross profit | 1,324,086 | 970,903 | 3,268,104 | 2,710,436 |
Operating expenses: | ||||
Selling expenses | 2,590 | 707 | 12,176 | 8,039 |
General and administrative expenses | 2,861,264 | 2,757,006 | 8,113,333 | 6,731,167 |
Total operating expenses | 2,863,854 | 2,757,713 | 8,125,509 | 6,739,206 |
Loss from operations | (1,539,768) | (1,786,810) | (4,857,405) | (4,028,770) |
Non-operating income (expense) | ||||
Interest income | 2,477 | 2,243 | 4,696 | 4,524 |
Interest expense | (138,684) | (123,866) | (282,058) | (291,109) |
Other expense | (308,763) | (960,937) | ||
Change in fair value of derivative liability | 373,339 | 958,868 | ||
Amortization of debt discount | (1,114,573) | (2,740,349) | (2,190,501) | (4,230,862) |
Foreign currency transaction (loss) gain | (19,588) | 3,620 | (78,946) | (35,681) |
Total other expense | (1,205,792) | (2,858,352) | (2,548,878) | (4,553,128) |
Loss before income taxes | (2,745,560) | (4,645,162) | (7,406,283) | (8,581,898) |
Income tax expense | ||||
Net loss | (2,745,560) | (4,645,162) | (7,406,283) | (8,581,898) |
Net income (loss) attributed to noncontrolling interest | 568 | (23,807) | 20,188 | (25,130) |
Net loss attributed to Novo Integrated Sciences, Inc. | (2,746,128) | (4,621,355) | (7,426,471) | (8,556,768) |
Comprehensive loss: | ||||
Foreign currency translation gain (loss) | 750,067 | (196,683) | 860,764 | (617,665) |
Comprehensive loss: | $ (1,995,493) | $ (4,841,845) | $ (6,545,519) | $ (9,199,563) |
Weighted average common shares outstanding - basic | 17,642,829 | 7,933,492 | 17,184,569 | 5,646,937 |
Weighted average common shares outstanding - diluted | 17,642,829 | 7,933,492 | 17,184,569 | 5,646,937 |
Net loss per common share - basic | $ (0.16) | $ (0.59) | $ (0.43) | $ (1.52) |
Net loss per common share - diluted | $ (0.16) | $ (0.59) | $ (0.43) | $ (1.52) |
Condensed Consolidated Balance Sheets - USD ($) | Feb. 29, 2024 | Aug. 31, 2023 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 651,747 | $ 416,323 |
Accounts receivable, net | 2,153,914 | 1,467,028 |
Inventory, net | 947,351 | 1,106,983 |
Other receivables | 1,048,596 | 1,051,584 |
Prepaid expenses and other current assets | 217,619 | 346,171 |
Total current assets | 5,019,227 | 4,388,089 |
Property and equipment, net | 5,246,241 | 5,390,038 |
Intangible assets, net | 15,205,967 | 16,218,539 |
Right-of-use assets, net | 1,916,900 | 1,983,898 |
Goodwill | 7,560,936 | 7,582,483 |
TOTAL ASSETS | 34,949,271 | 35,563,047 |
Current Liabilities: | ||
Accounts payable | 2,173,667 | 3,513,842 |
Accrued expenses | 1,328,828 | 1,233,549 |
Accrued interest (including amounts to related parties) | 477,480 | 382,666 |
Government loans and notes payable, current portion | 93,488 | 277,405 |
Convertible notes payable, net of discount of $2,004,245 | 1,773,533 | 558,668 |
Derivative liability | 2,312,921 | |
Contingent liability | 27,756 | 61,767 |
Debentures, related parties | 914,219 | 916,824 |
Finance lease liability | 5,788 | 11,744 |
Operating lease liability, current portion | 417,342 | 415,392 |
Total current liabilities | 9,959,061 | 7,904,858 |
Government loans and notes payable, net of current portion | 64,016 | 65,038 |
Operating lease liability, net of current portion | 1,639,391 | 1,693,577 |
Deferred tax liability | 1,396,519 | 1,400,499 |
TOTAL LIABILITIES | 13,058,987 | 11,063,972 |
Commitments and contingencies | ||
Novo Integrated Sciences, Inc. | ||
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at February 29, 2024 and August 31, 2023, respectively | ||
Common stock; $0.001 par value; 499,000,000 shares authorized; 17,748,320 and 15,759,325 shares issued and outstanding at February 29, 2024 and August 31, 2023, respectively | 17,749 | 15,760 |
Additional paid-in capital | 96,082,626 | 90,973,316 |
Common stock to be issued (17,375 and 91,138 shares at February 29, 2024 and August 31, 2023) | 44,443 | 1,217,293 |
Other comprehensive gain (loss) | 503,381 | (357,383) |
Accumulated deficit | (74,459,512) | (67,033,041) |
Total Novo Integrated Sciences, Inc. stockholders’ equity | 22,188,687 | 24,815,945 |
Noncontrolling interest | (298,403) | (316,870) |
Total stockholders’ equity | 21,890,284 | 24,499,075 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | 34,949,271 | 35,563,047 |
Related Party [Member] | ||
Current Liabilities: | ||
Due to related parties | $ 434,039 | $ 533,001 |